IGNYTE-3 sites:

State	City	Institute
Arizona	Gilbert	Banner MD Anderson
California	La Jolla	UCSD Moores Cancer Center
	Los Angeles	USC
		The Angeles Clinic
	Orange	University of California, Irvine
	San Francisco	San Francisco Oncology Associates
		University of California San Francisco
	Santa Monica	UCLA
	Stanford	Stanford Cancer Institute
Disctric of Columbia	Washington	Washington Hospital Center
Florida	Tampa	Moffitt Cancer Center
Iowa	Iowa City	University of Iowa
Illinois	Park Ridge	Advocate Lutheran General Hospital
Kansas	Westwood	University of Kansas
Kentucky	Louisville	University of Louisville
North Carolina	Chapel Hill	University of North Carolina
	Durham	Duke University
New Jersey	Camden	MD Anderson Cancer Center at Cooper
	Hackensack	Hackensack University Medical Center
	Morristown	Atlantic Health System
New York	Bronx	Montefiore Medical Center
	New Hyde Park	Northwell Health
	Stony Brook	Stony Brook University
Pennsylvania	Philadelphia	Fox Chase Cancer Center
		Thomas Jefferson University
	Pittsburgh	University of Pittsburgh Medical Center
Tennessee	Germantown	West Cancer Center
	Knoxville	University of Tennessee
Texas	Dallas	Texas Oncology PA
		UT Southwestern
Utah	Murray	Intermountain Health
	St. George	Intermountain Health

Since the list of clinical trial sites is often updated, it is essential to refer to the latest information available. You can verify the list provided above by contacting Replimune at clinicaltrials@replimune.com or visiting our Replimune website at replimune.com/clinical-trials/ignyte-3/ for the latest updates on new trial locations and how to join.

Important: Vusolimogene oderparepvec (RP1) is an investigational therapy and its use alone or in combination with OPDIVO® has not been proven to be safe or effective, and has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agency outside of the US.

Replimune®

Are you struggling with advanced melanoma that stopped responding to standard treatments?



IGNYTE-3 STUDY

Evaluating RP1 and OPDIVO® for patients with advanced melanoma that has progressed on certain immunotherapies (anti-PD-1 & anti-CTLA-4).

Important: Vusolimogene oderparepvec (RP1) is an investigational therapy and its use alone or in combination with OPDIVO® has not been proven to be safe or effective, and has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agency outside of the US.

Replimune®

Do you have advanced melanoma?

If you have a serious type of skin cancer called advanced melanoma that has gotten worse even after treatment with drugs like anti-PD-1 (such as OPDIVO® or KEYTRUDA®) and anti-CTLA-4 (like YERVOY®), or if you are ineligible for anti-CTLA-4 (YERVOY®) treatment, you might be interested in joining a research study. This study is testing a new treatment called vusolimogene oderparepvec (abbreviated as VO, also known as RP1) in combination with OPDIVO®. It is intended to work by attacking the cancer cells directly while also helping your body's immune system fight against the cancer.

What is the purpose of the IGNYTE-3 trial?

- IGNYTE-3 is a **follow-up trial to the IGNYTE study, which has completed enrollment** of patients with advanced melanoma whose disease got worse on anti-PD-1 therapy.
- Now, the IGNYTE-3 trial is **intended to study this combination treatment in a larger group** of patients with advanced melanoma.
- The objective of the IGNYTE-3 trial is to see if combining RP1 with OPDIVO® can help you live longer compared to several current therapies used for patients whose melanoma didn't respond to an anti-PD-1 and/or an anti-CTLA-4 drug.

Am I eligible to participate?

You may potentially be a candidate if you meet **all of the following**:

- Are 12 years old or older.
- Have advanced skin melanoma (stages 3b to 4) that cannot be removed with surgery.
- Should not be diagnosed with primary mucosal or uveal melanoma.
- Have at least one measurable tumor.
- Your melanoma has progressed after receiving anti-PD-1 and anti-CTLA-4 treatments, or you are not eligible for anti-CTLA-4 treatment.
  - You may be eligible to join if your physician previously deemed you ineligible for anti-CTLA-4 treatment.
- Should not have received more than two lines of systemic therapy for advanced melanoma.

Your doctor can check if you fit these requirements.
Please note that this is not the full list of criteria for joining the study.

What will happen if I participate in this study?

If you meet the criteria, you'll be randomly assigned to one of two treatment groups: either RP1 with OPDIVO® or your doctor's chosen therapy. **You'll be part of the study for about 5 years, divided into three parts:**

1

Screening
(Up to 4 weeks)

You'll have **tests and checks** to see if you can join the study.

2

Study Treatment
(Up to 2 years)

You'll receive up to **8 doses of RP1** over the first 16 weeks with the possibility of getting additional doses throughout the study period. OPDIVO® treatment will begin with the second dose of RP1. If you're not in the study group, your doctor will give you **treatments according to standard guidelines***. After you start treatment, you will have regular exams, imaging, and testing.

3

Follow-Up
(Up to 3 years)

After the treatment, your doctor and the study team will keep an eye on you from the first dose of study treatment until 60 days after your last dose of RP1, and 100 days after your last dose of OPDIVO®, as appropriate. If you're not in the study group, you'll have check-ups 60 to 100 days after your last dose of your doctor's chosen therapy. You will continue to be monitored for up to 3 years after you receive the first dose of treatment.

What's next?

- Check if you meet the requirements.
- Talk to your doctor or contact a clinical trial site for IGNYTE-3 that is enrolling to find out if you may be able to join.
- Visit the Replimune webpage replimune.com/clinical-trials/ignyte-3/ to learn more about this study. (**Scan the QR code.**)

Important: Vusolimogene oderparepvec (RP1) is an investigational therapy and its use alone or in combination with OPDIVO® has not been proven to be safe or effective, and has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agency outside of the US.

*Standard treatments may involve combination therapy (OPDUALAG™), monotherapy (OPDIVO® or KEYTRUDA®), or chemotherapy (DTIC-Dome® , TEMODAR® , TAXOL® , or ABRAXANE®).